Executive Summary

Oct 2019
PROSPECTS
Analgesics continues to benefit from Egypt’s strong self-medication culture

Huge sales of OTC analgesics are generated in Egypt on an annual basis and 2019 was no exception as further strong increases in demand were seen. The main reason for this situation is that self-medication is extremely common in Egypt, with the majority of people preferring to consult a pharmacist when facing discomfort or the initial symptoms of mild and moderate illness.

Aspirin and ibuprofen register slower demand as all categories record strong growth

All categories of OTC analgesics registered positive growth in Egypt during 2019, with very strong growth in demand recorded in most categories. As the country’s economy continues to improve, with rising spending due to low levels of pressure on household budgets, some analgesics categories are facing slower growth in demand than in previous years.

Strong growth due to population growth and consistent demand throughout the year

Analgesics is set to continue registering consistently strong positive sales growth throughout the forecast period. Among the main drivers of categories dynamic performance are Egypt’s growing population, including strong increases expected in the numbers of babies and children among the country’s population.

COMPETITIVE LANDSCAPE
GSK’s range of strong brands ensures the company’s ongoing leadership

GSK Consumer Healthcare remained the leading player in analgesics in 2019. The company offers three of the four leading brands in the category: Panadol, Cataflam and Voltaren.

Brufen by Abbott Laboratories is still the leading brand in analgesics

Abbott Laboratories maintain second position in analgesics in 2019 due to the enduring popularity of its ibuprofen brand Brufen, which remains the leading brand of analgesics in Egypt. In particular, Brufen is extremely popular in its paediatric variant, which is very commonly given to children by their parents.

Rising demand for diclofenac benefits Novartis

Novartis Egypt maintained third position in analgesics in 2019 due to the popularity of its brand Catafast, which is the second leading name in diclofenac. It should also be noted that the leading diclofenac brand in Egypt, Cataflam, is still produced by Novartis EG despite being marketed by GSK Consumer Healthcare following the latter company’s acquisition of the rights to the brand.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in Egypt

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Egypt with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Egypt, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Egypt market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in Egypt?
  • What are the major brands in Egypt?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in Egypt - Category analysis

HEADLINES

PROSPECTS

Analgesics continues to benefit from Egypt’s strong self-medication culture
Aspirin and ibuprofen register slower demand as all categories record strong growth
Strong growth due to population growth and consistent demand throughout the year

COMPETITIVE LANDSCAPE

GSK’s range of strong brands ensures the company’s ongoing leadership
Brufen by Abbott Laboratories is still the leading brand in analgesics
Rising demand for diclofenac benefits Novartis

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in Egypt - Industry Overview

EXECUTIVE SUMMARY

Demand continues to increase in consumer health despite high inflation
Strong self-medication culture support sales in all OTC categories
Stability in the competitive environment the result of regulatory burdens
Strict regulations limit product distribution to chemists/pharmacies
Further sales growth anticipated over the forecast period

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources